Bridging Academia and Industry to Accelerate Drug Development and Translation
We are committed to integrating AI-driven design with key materials and process development technologies to accelerate the translation of new drugs from research and development to clinical application.
The Accelerator for New Drug Development, established under the National Health Research Institutes (NHRI), is dedicated to integrating AI-driven drug design, key material supply, and process development technologies to create an end-to-end drug development acceleration platform spanning early-stage research through preclinical development. By leveraging national-level R&D resources and multidisciplinary expertise, we support academic, research, and industry partners in Taiwan and worldwide to accelerate the development of new therapeutics.
This initiative brings together three core platforms—the Value-Added Medicinal Chemistry Innovation Center (VMIC), the Key Materials Innovation Center (KMIC), and the AI-Driven Drug Design Innovation Center (AMIC)—to establish an integrated R&D framework encompassing molecular design, compound development, key material library development, and process optimization. Through efficient and flexible technical services, we help our partners reduce R&D risks and costs, enhance the efficiency of innovative drug development, and advance clinical translation and industrial applications.
